Biological activity validation of a computationally designed Rituximab/CD3 T cell engager targeting CD20+ cancers with multiple mechanisms of action

enthalten in: Antibody therapeutics | 2021

von Cai, W. | Dong, J. | Gallolu Kankanamalage, S. | +11